Lanthanum Viatris

Lanthanum, the active ingredient in Lanthanum Viatris, is a phosphate binder presented as an oral formulation for oral use. It is employed to treat hyperphosphatemia in patients with chronic kidney disease who are receiving dialysis. The drug binds dietary phosphate in the gastrointestinal tract, creating insoluble complexes that are excreted, thereby lowering serum phosphate levels.

GNH USA supplies Lanthanum Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance.

Lanthanum Viatris is a phosphate binder indicated for conditions associated with elevated serum phosphate.

- Hyperphosphatemia in chronic kidney disease on dialysis: reduces serum phosphate levels by binding dietary phosphate. - End‑stage renal disease (ESRD) patients: helps maintain phosphate balance to prevent vascular calcification. - Chronic kidney disease (CKD) not yet on dialysis (when prescribed): lowers phosphate absorption to support renal management.

Lanthanum may cause gastrointestinal and systemic adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild stomach upset. - Constipation: reduced bowel movements. - Abdominal pain: discomfort in the abdomen. - Diarrhea: loose stools.

Serious or Rare Side Effects: - Severe constipation or bowel obstruction: may require medical attention. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Hypercalcemia: elevated calcium levels in rare cases.

When prescribing Lanthanum, clinicians should consider several safety precautions to minimize risks. - Monitor serum phosphate: regularly check levels to adjust dose. - Assess calcium and magnesium: avoid imbalances that could lead to complications. - Avoid use in patients with bowel obstruction: risk of worsening blockage. - Caution in pregnancy and lactation: limited data, weigh benefits versus risks. - Drug interactions: separate administration from other oral phosphate binders or mineral supplements by at least 2 hours. - Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture.

Lanthanum can affect the absorption of other oral medications, leading to clinically relevant interactions.

Major Interactions (Avoid): - Other phosphate binders (e.g., sevelamer, calcium carbonate): concurrent use reduces efficacy of both agents. - Iron supplements (ferrous sulfate): lanthanum markedly decreases iron absorption.

Moderate Interactions (Monitor Closely): - Tetracycline antibiotics (doxycycline): reduced antibiotic absorption; separate dosing by at least 2 hours. - Fluoroquinolone antibiotics (ciprofloxacin): decreased bioavailability; stagger administration. - Vitamin D analogs (calcitriol): may increase calcium absorption; monitor calcium levels.